Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images) Pfizer presses forward with once-daily GLP-1 pill in long-awaited move Pfizer is making a move on its obesity pipeline after multiple quarters of questions from investors and analysts
7.2 Increased leaky gut HFD shifts a high diversity microbiome to a low diversity state, enhancing microbial pathogens and leading to degradation of the gut epithelial barrier, thereby increasing intestinal permeability
It also plays a vital role in Phase II detoxification in the liver
This is likely due to greater weight loss seen in this trial, approximately 21% with 15 mg dosing, far exceeding the 14% weight loss observed in GLP-1 RA trials [14, 16, 19, 20, 23]
Institute of Medicine
HELP & ADVICE CONTACT If you're suffering from a sartorial block or need a hand hunting down something extra special, we're here to help